Rare Disease Therapeutics · Cell & Gene Therapy
PTC Therapeutics revenue, results and funding
PTC Therapeutics filed revenue of $1.7B for 2025.
Data updated Nov 18, 2026 · Back to the company report
$1.7BRevenue, 2025
$682.6MNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1.7B | $682.6M | $2.9B | $36.9M | $14M | $8.9M | $74.5M | $455.2M | $866.9M | $984.6M | – | – |
| 2024 | $806.8M | −$363.3M | $1.7B | $17.6M | $176k | $6.5M | $74.6M | $534.5M | −$302.6M | $779.7M | $285.4M | – |
| 2023 | $937.8M | −$626.6M | $1.9B | $14.2M | −$69.5M | $28.4M | $101.6M | $666.6M | −$439.5M | $594M | $284.2M | – |
| 2022 | $698.8M | −$559M | $1.7B | $4.9M | −$28.5M | $32M | $110.3M | $651.5M | −$447.4M | $279.8M | $571.7M | – |
| 2021 | $538.6M | −$523.9M | $1.9B | $7.7M | $5.6M | $28.2M | $103.5M | $540.7M | −$374.4M | $189.7M | $281.9M | – |
| 2020 | $380.8M | −$438.2M | $2.2B | $26.4M | $35.2M | $17.8M | $70.3M | $477.6M | −$431.8M | $208.8M | $309.1M | – |
| 2019 | $307M | −$251.6M | $1.6B | $2.1M | $11.7M | $13.8M | $42.1M | $257.5M | −$241.2M | $288M | $293.9M | $0 |
| 2018 | $264.7M | −$128.1M | $1.1B | $1.6M | −$29k | $7.1M | $33.3M | $172M | −$115.7M | $169.5M | $141.3M | $48.9M |
| 2017 | $194.4M | −$79M | $391.7M | $1.1M | $1.3M | $3.1M | $30.6M | $117.5M | −$64.3M | $111.8M | $145M | $0 |
| 2016 | $82.7M | −$142.1M | $269.3M | $943k | $569k | $1.8M | $35M | $117.6M | −$132.1M | $58.3M | $98.2M | $0 |
| 2015 | $36.8M | −$170.4M | $365.3M | $111k | $485k | $2.7M | $34M | $121.8M | −$167.1M | $58M | $91.8M | – |
| 2014 | $25.2M | −$93.8M | $333.2M | $0 | −$4.7M | $4.7M | $19.3M | $79.8M | −$99.4M | $49.7M | – | – |
| 2013 | $34.7M | −$51.6M | $151.9M | $2k | – | $846k | $8.4M | $54.9M | −$45.4M | $15.4M | – | – |
| 2012 | $33.9M | −$26.2M | $13.1M | $2k | – | $189k | $2.3M | $46.1M | −$26.8M | $2.7M | $439k | – |
| 2011 | $105.4M | $30.9M | – | $2.1k | −$2.3M | $165k | $2.8M | $58.7M | $30.6M | $28.4M | – | – |
Sources: SEC
How to cite
PTC Therapeutics, Financials. Alion, Nov 18, 2026. https://alion.io/company/ptcbio/financials
